Skip to content
2000
Volume 18, Issue 2
  • ISSN: 1570-1646
  • E-ISSN: 1875-6247

Abstract

Background: Leptospirosis is a prevalent zoonotic disease caused by Leptospira interrogans bacterium. Despite the importance of this disease, traditional strategies including attenuated and inactivated vaccines have not been able to prevent leptospirosis. Objective: Hence, this study was designed to develop a novel poly-epitope fusion protein vaccine against Leptospirosis. Methods: To do so, the best epitopes of OmpA, LipL45, OmpL1, LipL41 and LipL21 proteins were predicted. Then, the best-predicted epitopes were applied to assemble IFN-γ, MHC I binding, B cell and MHC II binding fragments, and heparin-binding hemagglutinin adhesion was used as a molecular adjuvant. After designing the vaccine, the most important features of it, including physicochemical parameters, protein structures and protein-protein interaction, were evaluated. Finally, the nucleotide sequence of the designed vaccine was used for codon adaptation. Results: The results showed that the designed vaccine was a stable protein with antigenicity of 0.913, which could dock to its receptor. The results also suggested that the nucleotide sequence of the designed vaccine could be expressed in the prokaryotic system. Conclusion: Based on the results of this study, it can be concluded that the vaccine can be a promising candidate to control Leptospirosis.

Loading

Article metrics loading...

/content/journals/cp/10.2174/1570164617666200319144331
2021-04-01
2024-11-18
Loading full text...

Full text loading...

/content/journals/cp/10.2174/1570164617666200319144331
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test